Beta-blocking medicine sales in Canada are seeing a declining trend from 2024 to 2028, with forecasted values dropping from 246.9 million CAD in 2024 to 223.2 million CAD in 2028. Compared to 2023, when the sales stood at 252.0 million CAD, there is a noticeable decrease. The year-on-year percentage decline for these years suggests a steady contraction in the market. Over the five-year period, the compound annual growth rate (CAGR) indicates a persistent decrease in market size.

Future trends to watch include potential market influences such as generic medicine penetration, healthcare policy changes, and evolving healthcare needs, which may affect the demand for beta-blockers. Monitoring innovations in cardiovascular treatments could also impact market dynamics.

Download as XLS

More about Beta-Blocker Industry 2025-2029